RU2008118100A - Лечение и профилактика микроангиопатий - Google Patents

Лечение и профилактика микроангиопатий Download PDF

Info

Publication number
RU2008118100A
RU2008118100A RU2008118100/15A RU2008118100A RU2008118100A RU 2008118100 A RU2008118100 A RU 2008118100A RU 2008118100/15 A RU2008118100/15 A RU 2008118100/15A RU 2008118100 A RU2008118100 A RU 2008118100A RU 2008118100 A RU2008118100 A RU 2008118100A
Authority
RU
Russia
Prior art keywords
solvates
salts
formula
microangiopathies
chloro
Prior art date
Application number
RU2008118100/15A
Other languages
English (en)
Russian (ru)
Inventor
Элизабет ПЕРЦБОРН (DE)
Элизабет ПЕРЦБОРН
Франк МИССЕЛЬВИТЦ (DE)
Франк Миссельвитц
Original Assignee
Байер ХельсКер АГ (DE)
Байер ХельсКер АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер ХельсКер АГ (DE), Байер ХельсКер АГ filed Critical Байер ХельсКер АГ (DE)
Publication of RU2008118100A publication Critical patent/RU2008118100A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2008118100/15A 2005-10-10 2006-09-27 Лечение и профилактика микроангиопатий RU2008118100A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005048824A DE102005048824A1 (de) 2005-10-10 2005-10-10 Behandlung und Prophylaxe von Mikroangiopathien
DE102005048824.2 2005-10-10

Publications (1)

Publication Number Publication Date
RU2008118100A true RU2008118100A (ru) 2009-11-20

Family

ID=37492407

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008118100/15A RU2008118100A (ru) 2005-10-10 2006-09-27 Лечение и профилактика микроангиопатий

Country Status (17)

Country Link
US (1) US20100160301A1 (US07585860-20090908-C00083.png)
EP (1) EP1937271A1 (US07585860-20090908-C00083.png)
JP (1) JP2009511513A (US07585860-20090908-C00083.png)
KR (1) KR20080067647A (US07585860-20090908-C00083.png)
CN (1) CN101325957A (US07585860-20090908-C00083.png)
AU (1) AU2006301650A1 (US07585860-20090908-C00083.png)
BR (1) BRPI0617202A2 (US07585860-20090908-C00083.png)
CA (1) CA2624963A1 (US07585860-20090908-C00083.png)
CR (1) CR9878A (US07585860-20090908-C00083.png)
DE (1) DE102005048824A1 (US07585860-20090908-C00083.png)
EC (1) ECSP088358A (US07585860-20090908-C00083.png)
IL (1) IL190745A0 (US07585860-20090908-C00083.png)
NO (1) NO20082120L (US07585860-20090908-C00083.png)
RU (1) RU2008118100A (US07585860-20090908-C00083.png)
SV (1) SV2009002865A (US07585860-20090908-C00083.png)
WO (1) WO2007042146A1 (US07585860-20090908-C00083.png)
ZA (1) ZA200803048B (US07585860-20090908-C00083.png)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
EP1934208B1 (de) 2005-10-04 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid
WO2007092961A2 (en) * 2006-02-09 2007-08-16 University Of New Orleans Research & Technologies Foundation Antibacterial agents
CA2679659C (en) * 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
DE102007018662A1 (de) * 2007-04-20 2008-10-23 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie
WO2009018807A1 (de) * 2007-08-06 2009-02-12 Schebo Biotech Ag Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie
JP5422569B2 (ja) * 2008-02-21 2014-02-19 サノフイ 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
CN104693139B (zh) * 2011-01-07 2017-04-19 浙江九洲药业股份有限公司 一种合成利伐沙班中间体的新工艺
CN102746287B (zh) * 2012-06-21 2014-05-28 成都苑东药业有限公司 一种恶唑烷酮化合物及其制备方法
CN103724336B (zh) * 2013-12-24 2015-10-21 悦康药业集团有限公司 一种新型抗凝血药物的合成方法
CN104402876A (zh) * 2014-11-25 2015-03-11 沈阳药科大学 噁唑烷酮类化合物及其应用
CN104478866B (zh) * 2014-12-05 2017-07-07 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104447728B (zh) * 2014-12-05 2017-01-04 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104478869B (zh) * 2014-12-05 2017-04-12 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104447730B (zh) * 2014-12-05 2017-11-07 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104497008B (zh) * 2014-12-09 2016-11-16 广东东阳光药业有限公司 取代噁唑烷酮类化合物及其使用方法和用途
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
US11608320B2 (en) 2020-02-02 2023-03-21 Kuwait University Oxazolidinone hydroxamic acid derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2811555A (en) * 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
LU80081A1 (fr) * 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) * 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0610265B1 (en) * 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
US5349045A (en) * 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
ATE181735T1 (de) * 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
SV2009002865A (es) 2009-01-14
KR20080067647A (ko) 2008-07-21
ECSP088358A (es) 2008-06-30
BRPI0617202A2 (pt) 2011-07-19
US20100160301A1 (en) 2010-06-24
AU2006301650A1 (en) 2007-04-19
IL190745A0 (en) 2008-12-29
CR9878A (es) 2008-07-29
JP2009511513A (ja) 2009-03-19
DE102005048824A1 (de) 2007-04-12
EP1937271A1 (de) 2008-07-02
NO20082120L (no) 2008-06-18
CN101325957A (zh) 2008-12-17
WO2007042146A1 (de) 2007-04-19
CA2624963A1 (en) 2007-04-19
ZA200803048B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
RU2008118100A (ru) Лечение и профилактика микроангиопатий
RU2008116828A (ru) Комбинированный метод терапии замещенными оксазолидинонами для профилактики и лечения нарушений церебрального местного кровообращения
CA2451258A1 (en) Combination therapy of substituted oxazolidinones
RU2492167C2 (ru) Производные аминотриазола в качестве агонистов alх
CA2668068A1 (en) Combination therapy of substituted oxazolidinones
RU2007106180A (ru) Производные индола, индазола или индолина
PE20011119A1 (es) Composiciones farmaceuticas de agonista/antagonista de estrogenos para el tratamiento de afecciones que responden a un aumento de testosterona
RU2008128452A (ru) Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
RU2012134306A (ru) Азотосодержащие производные гетероарилов
JP2013525438A5 (US07585860-20090908-C00083.png)
CO6220933A2 (es) Formulaciones de dosis unitaria y metdods para el tratamiento de la trombosis con un inhibidor oral del facror xa
PE20121354A1 (es) Inhibidores del virus de la hepatitis c
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
PE20121084A1 (es) Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
AR070811A1 (es) Derivados de 1- bencil-3- hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40
RU2008110917A (ru) ПРОИЗВОДНЫЕ 7-(2-АМИНО-1-ГИДРОКСИ-ЭТИЛ)-4-ГИДРОКСИБЕНЗОТИАЗОЛ-2(3Н)-ОНА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ
AR082458A1 (es) Combinacion que comprende un farmaco antipsicotico y un agonista de taar1
JP2019518770A5 (US07585860-20090908-C00083.png)
RU2007140244A (ru) Произвдное соединение пропан-1,3-диона или его соль
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
RU2014123109A (ru) Антибиотические производные 2-оксо-оксазолидин-3, 5-диила
AR070812A1 (es) Derivados de 1- bencil-3- hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40
RU2008135979A (ru) Соединения гидроксиакрилаимда
RU2010109388A (ru) Производные 5-амино-4,6-дизамещенного индола и 5-амино-4,6-дизамещенного индолина как модуляторы калиевых каналов

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20091211